Diploma PLC (LON:DPLM – Get Free Report) has been given an average rating of “Moderate Buy” by the seven analysts that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is GBX 5,634.29.
DPLM has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft increased their target price on Diploma from GBX 6,000 to GBX 6,200 and gave the stock a “buy” rating in a report on Wednesday, January 14th. Berenberg Bank reiterated a “buy” rating and set a GBX 6,350 price objective on shares of Diploma in a research note on Wednesday, November 19th. Finally, Peel Hunt reissued a “buy” rating and issued a GBX 6,150 target price on shares of Diploma in a report on Friday, December 19th.
Read Our Latest Analysis on DPLM
Insider Transactions at Diploma
Diploma Stock Performance
DPLM opened at GBX 5,375 on Thursday. The company has a quick ratio of 0.80, a current ratio of 2.17 and a debt-to-equity ratio of 62.17. Diploma has a 12-month low of GBX 3,532 and a 12-month high of GBX 5,760. The business has a 50 day moving average of GBX 5,438.25 and a 200-day moving average of GBX 5,405.44. The stock has a market cap of £7.21 billion, a price-to-earnings ratio of 39.15, a PEG ratio of 2.82 and a beta of 0.75.
Diploma (LON:DPLM – Get Free Report) last announced its quarterly earnings results on Monday, December 8th. The company reported GBX 176 EPS for the quarter. Diploma had a net margin of 9.25% and a return on equity of 13.18%. On average, equities research analysts expect that Diploma will post 163.7995512 earnings per share for the current year.
Diploma Company Profile
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
See Also
- Five stocks we like better than Diploma
- The day the gold market broke
- Buy this Gold Stock Before May 2026
- Trump Planning to Use Public Law 63-43: Prepare Now
- Forget AI, This Will Be the Next Big Tech Breakthrough
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.
